» Authors » Dariusz Ziora

Dariusz Ziora

Explore the profile of Dariusz Ziora including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 78
Citations 265
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Ziora D
Adv Respir Med . 2024 Sep; 92(5):348-355. PMID: 39311112
Small airway dysfunction (SAD) is a pathological process that affects the bronchioles and non-cartilaginous airways below 2 mm in diameter. This short review presents a link between SAD and IPF....
2.
Rzepka-Wrona P, Skoczynski S, Piotrowski W, Jassem E, Ziora D, Barczyk A
JMIR Res Protoc . 2023 Nov; 12:e44802. PMID: 37976081
Background: "Interstitial lung disease" (ILD) is a broad term encompassing diseases of different backgrounds. "Interstitial pneumonia with autoimmune features" (IPAF) is a recent term that implies the presence of autoimmunity....
3.
Jastrzebski D, Kostorz-Nosal S, Galle D, Galeczka-Turkiewicz A, Warzecha J, Majewski S, et al.
Health Sci Rep . 2023 Aug; 6(8):e1449. PMID: 37599655
Background And Aims: Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single-arm, open-label, nonrandomized study aimed to determine the influence of antifibrotic treatment on...
4.
Sikora M, Jastrzebski D, Pilzak K, Osiadlo G, Ziora D, Zebrowska A
Respir Physiol Neurobiol . 2023 Aug; 316:104139. PMID: 37579930
The purpose of the study was to determine the level of physical fitness assessed based on the physiological parameters and intensity of daily physical activity (PA) of patients with idiopathic...
5.
Majewski S, Bialas A, Barczyk A, Batura-Gabryel H, Buchczyk M, Doboszynska A, et al.
J Clin Med . 2023 Jul; 12(14). PMID: 37510750
Nintedanib is a disease-modifying agent licensed for the treatment of IPF. Data on Polish experience with nintedanib in IPF are lacking. The present study aimed to describe the safety and...
6.
Sikora M, Jastrzebski D, Pilzak K, Ziora D, Hall B, Zebrowska A
Respir Physiol Neurobiol . 2023 Apr; 313:104064. PMID: 37076026
This study aimed to investigate the physical functioning predictors for health-related quality of life (HRQL) decline in patients with idiopathic interstitial fibrosis (IPF), sarcoidosis and other interstitial lung disease (ILD)....
7.
Kostorz-Nosal S, Jastrzebski D, Zebrowska A, Bartoszewicz A, Ziora D
Medicina (Kaunas) . 2022 Nov; 58(11). PMID: 36363507
Background: Thoracic surgery is a recommended treatment option for non-small cell lung cancer patients. An important part of a patient’s therapy, which helps to prevent postoperative complications and improve quality...
8.
Piotrowski W, Martusewicz-Boros M, Bialas A, Barczyk A, Batko B, Blasinska K, et al.
Adv Respir Med . 2022 Oct; 90(5):425-450. PMID: 36285980
The recommendations were developed as answers to previously formulated questions concerning everyday diagnostic and therapeutic challenges. They were developed based on a review of the current literature using the GRADE...
9.
Kostorz-Nosal S, Jastrzebski D, Kubicki P, Galle D, Galeczka-Turkiewicz A, Toczylowska B, et al.
J Clin Med . 2022 Jul; 11(13). PMID: 35806942
(1) Background: Pulmonary rehabilitation (PR) plays a significant therapeutic role for patients with idiopathic interstitial pneumonia (IIP). The study assessed the impact of physical activity on lung function measured by...
10.
Solich-Talanda M, Zebrowska A, Mikolajczyk R, Kostorz-Nosal S, Ziora D, Jastrzebski D, et al.
Front Physiol . 2021 Sep; 12:726434. PMID: 34566688
Given the previous evidence that breath-hold diving is a cause of physiological stress, this study aimed to determine whether a combination static and dynamic apnea would affect total oxidant status,...